ASX:OPT Opthea (OPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Opthea Stock (ASX:OPT) 30 days 90 days 365 days Advanced Chart Get Opthea alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume504,572 shsAverage VolumeN/AMarket Capitalization$790.69 millionP/E RatioN/ADividend Yield0.24%Price TargetN/AConsensus RatingN/A Company OverviewOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More… Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Stock News HeadlinesRegal says Platinum business a ‘melting ice cube’May 7 at 5:10 PM | afr.comOpthea, with shares still suspended, cuts workforce by 65% after drug trials cancelledApril 9, 2025 | msn.comThis picture could hold the secret to the market's next move.A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …May 10, 2025 | Weiss Ratings (Ad)Regal Partners shares slide on drop in funds under managementApril 9, 2025 | msn.comHealth Check: It’s a CEO changing of the guard at Mach 7 and Universal BiosensorsMarch 31, 2025 | msn.comOpthea in active talks with funders after second trial failsMarch 31, 2025 | afr.comWhy this sold-off ASX All Ords dividend stock is 'well placed to generate long-term shareholder value'March 27, 2025 | msn.comHedge Fund Regal Among Stock Pickers Burned by Biotech CrashMarch 27, 2025 | bloomberg.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions How were Opthea's earnings last quarter? Opthea Limited (ASX:OPT) released its earnings results on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.00. Opthea had a negative net margin of 182,616.58% and a positive trailing twelve-month return on equity of 543.34%. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include Skyworks Solutions (SWKS), Teladoc Health (TDOC), Vaxart (VXRT), Zion Oil & Gas (ZN), AST SpaceMobile (ASTS), Appian (APPN) and American Well (AMWL). Company Calendar Last Earnings8/09/2019Today5/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:OPT CIKN/A Webwww.opthea.com Phone61 3 9826 0399FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-220,240,000.00 Net Margins-182,616.58% Pretax MarginN/A Return on Equity543.34% Return on Assets-83.43% Debt Debt-to-Equity Ratio-186.85 Current Ratio2.94 Quick Ratio4.25 Sales & Book Value Annual Sales$199,005.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.29 Book ValueA($0.11) per share Price / BookN/AMiscellaneous Outstanding Shares1,230,000,000Free FloatN/AMarket Cap$790.69 million OptionableNot Optionable Beta1.61 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (ASX:OPT) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.